Several other analysts also recently commented on the company. BidaskClub downgraded Regeneron Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, April 16th. Cantor Fitzgerald reiterated a hold rating and set a $441.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, February 6th. Oppenheimer increased their price target on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an outperform rating in a report on Thursday, February 7th. Piper Jaffray Companies increased their price target on Regeneron Pharmaceuticals to $487.00 and gave the company an overweight rating in a report on Tuesday, February 26th. Finally, Jefferies Financial Group lowered their price target on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a hold rating on the stock in a report on Wednesday, April 17th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals presently has a consensus rating of Hold and an average price target of $397.44.
Shares of REGN opened at $312.56 on Thursday. The company has a current ratio of 4.58, a quick ratio of 3.78 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals has a 12 month low of $291.69 and a 12 month high of $442.00. The firm has a market cap of $34.16 billion, a price-to-earnings ratio of 15.79, a price-to-earnings-growth ratio of 1.46 and a beta of 1.08.
In related news, EVP Neil Stahl sold 9,853 shares of the firm’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total value of $3,012,456.22. Following the transaction, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at approximately $14,507,363. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the transaction, the director now directly owns 11,323 shares in the company, valued at $3,464,045.39. The disclosure for this sale can be found here. Insiders have sold a total of 141,968 shares of company stock worth $57,360,056 over the last three months. Insiders own 11.84% of the company’s stock.
Institutional investors have recently made changes to their positions in the stock. Capital Financial Planning LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $33,000. Landsberg Bennett & Dubbaneh LLC raised its holdings in Regeneron Pharmaceuticals by 13.5% in the 1st quarter. Landsberg Bennett & Dubbaneh LLC now owns 815 shares of the biopharmaceutical company’s stock worth $332,000 after purchasing an additional 97 shares during the period. Morgan Stanley raised its holdings in Regeneron Pharmaceuticals by 70.6% in the 3rd quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after purchasing an additional 192,236 shares during the period. Schaper Benz & Wise Investment Counsel Inc. WI raised its holdings in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 16,826 shares of the biopharmaceutical company’s stock worth $6,909,000 after purchasing an additional 216 shares during the period. Finally, Sontag Advisory LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $68,000. 67.61% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
See Also: How to Invest in Marijuana Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.